Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is at least 32.72% than its current record low price of $32.18. There was a 2.72% gain on 01/11/2019 that led the price to move at $42.71. At recent session, the prices were hovering between $40.84 and $42.84. This company shares are 94.57% off its target price of $83.1 and the current market capitalization stands at $1.89B. The recent change has given its price a 1.77% lead over SMA 50 and -42.86% deficit over its 52-week high. The stock witnessed 5.38% gains, -17.21% declines and -40.27% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AERI’s volatility during a week at 5.84% and during a month it has been found around 5.99%.Aerie Pharmaceuticals, Inc. (AERI) Top Holders
Institutional investors currently hold around $2.05 billion or 0% in AERI stock. Look at its top three institutional owners. Wellington Management Group Llp owns $247.88 million in Aerie Pharmaceuticals, Inc., which represents roughly 13.12% of the company’s market cap and approximately 12.12% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 3,887,580 shares of the stock are valued at $166.04 million. The third largest holder is Blackrock Inc., which currently holds $133.44 million worth of this stock and that ownership represents nearly 7.06% of its market capitalization.Aerie Pharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 104 institutional holders increased their position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by some 7,574,026 shares, 71 decreased positions by 3,124,384 and 27 held positions by 37,182,247. That puts total institutional holdings at 47,880,657 shares, according to SEC filings. The stock grabbed 27 new institutional investments totaling 985,815 shares while 25 institutional investors sold out their entire positions totaling 776,763 shares.Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insider Trades
Multiple company employees have indulged in significant insider trading. Aerie Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Scientific Officer Kopczynski Casey C. has sold 11,000 shares of Aerie Pharmaceuticals, Inc. (AERI) in trading session dated Jan. 02, 2019. These shares are worth $387,310 and were traded at $35.21 each. The SEC filing shows that Kopczynski Casey C. performed a sale of 11,000 shares. The Chief Scientific Officer disposed these shares by way of transaction on Dec. 03, 2018. The company’s shares were given away at $39.81 per share worth to an income of some $437,910 on account of Kopczynski Casey C..
Director, Cagle Gerald D., purchased 2,000 common shares of Aerie Pharmaceuticals, Inc. (AERI) in the open market. In a transaction dated Nov. 16, 2018, the shares were bought at an average price of $41.75, giving away a sum of $83,500. After this purchase, 19,800 common shares of AERI are directly owned by the insider, with total stake valued at $845,658.
In the transaction dated Nov. 01, 2018, the great number of shares disposed came courtesy the Chief Scientific Officer; Kopczynski Casey C. disposed a total of 11,000 shares at an average price of $53.87, amounting to approximately $592,570. The insider now directly owns 128,743 shares worth $5,498,614.Aerie Pharmaceuticals, Inc. (AERI) Analyst Guide
Several analysts have released their opinion on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.73 average brokerage recommendation.